Trial Profile
A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2014
Price :
$35
*
At a glance
- Drugs Ferucarbotran (Primary)
- Indications Liver cancer
- Focus Diagnostic use
- Sponsors Bayer
- 06 Jun 2014 New trial record